SOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that ...

A new study shows that the stage of normal cell development at which B cells transform into leukemic cells impacts treatment ...

Phase 3 study met primary and most key secondary clinical endpoints This marks the third developmental and epileptic encephalopathies (DEE) population for fenfluramine ...

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ('Clearmind” or the 'Company'), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to ...

First-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers with initial data expected in Q4 2025Marks the first submitted Clinica ...

Manchester’s inward investment agency MIDAS has launched a new life sciences prospectus showcasing the city-region's strength in the sector. Business leaders also hailed ...

Biotech M&A is heating up, making small-cap firms with breakthrough assets top acquisition targets and potential big winners ...